PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity.
Sign Up to like & getrecommendations! Published in 2017 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2017.2727
Abstract: PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity To the Editor In a study by Koren et al,1 proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors exhibited potent and persistent long-term efficacy in reducing… read more here.
Keywords: pcsk9 inhibitors; ldl cholesterol; mevalonate pathway; cholesterol ... See more keywords
Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Cardiology"
DOI: 10.1001/jamacardio.2017.2959
Abstract: Overview Pay-for-performance programs, which seek to better align incentives between insurers and clinicians, are increasingly being used to improve quality without necessarily increasing spending. For example, under Medicare’s hospital value-based payment program, reimbursements are based… read more here.
Keywords: pcsk9 inhibitors; based pricing; outcomes based; reimbursement ... See more keywords
Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Apheresis"
DOI: 10.1002/jca.21839
Abstract: Severe familial hypercholesterolaemia (FH) causes premature disability and death due to atherosclerotic cardiovascular disease and is refractory to standard lipid‐lowering therapies. Lipoprotein apheresis (LA) has long been a standard of care for patients with severe… read more here.
Keywords: lipoprotein apheresis; familial hypercholesterolaemia; pcsk9 inhibitors; severe familial ... See more keywords
Economic Evaluation of the PCSK9 Inhibitors in Prevention of the Cardiovascular Diseases
Sign Up to like & getrecommendations! Published in 2018 at "Current Cardiology Reports"
DOI: 10.1007/s11886-018-0993-8
Abstract: Purpose of ReviewThis review aims to explore and summarize the current literature on the cardiovascular disease (CVD) healthcare burden and determine the cost-effectiveness of the PCSK9 inhibitors.Recent FindingsThe CVD remain the largest cause of mortality… read more here.
Keywords: cost effectiveness; pcsk9 inhibitors; pcsk9; cvd ... See more keywords
The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Current Cardiology Reports"
DOI: 10.1007/s11886-019-1103-2
Abstract: Purpose of ReviewTo review the clinical rationale for use of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in clinical practice.Recent FindingsDespite widespread use of statins for lipid lowering, many patients at high cardiovascular risk… read more here.
Keywords: new face; risk; pcsk9 inhibitors; face hyperlipidemia ... See more keywords
Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0867-9
Abstract: The clinical importance and benefit of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors appears well established for the high-risk cardiovascular (CV) patient. This applies especially to the statin-intolerant patient or the patient who does… read more here.
Keywords: outcomes access; pcsk9 inhibitors; ldl; cholesterol ... See more keywords
Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness
Sign Up to like & getrecommendations! Published in 2020 at "PharmacoEconomics"
DOI: 10.1007/s40273-020-00936-0
Abstract: Background New pharmacological therapies for the treatment of cardiovascular disease (CVD) have emerged in recent years. The high rates of CVD and the need for long-term treatment to decrease risk factors makes cost-effectiveness crucial for… read more here.
Keywords: cost effectiveness; cost; pcsk9 inhibitors; standard care ... See more keywords
Economic evaluation of lipid lowering with PCSK9 inhibitors in patients with familial hypercholesterolemia: Methodological aspects.
Sign Up to like & getrecommendations! Published in 2019 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2019.06.900
Abstract: BACKGROUND AND AIMS Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proved to reduce low density lipoprotein cholesterol levels in numerous clinical trials. In two large clinical trials, PCSK9 inhibitor treatment reduced the risk of… read more here.
Keywords: pcsk9 inhibitors; patients familial; cost effective; familial hypercholesterolemia ... See more keywords
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia.
Sign Up to like & getrecommendations! Published in 2022 at "Drug discovery today"
DOI: 10.1016/j.drudis.2022.01.014
Abstract: When secreted into the circulation, proprotein convertase subtilisin kexin type 9 (PCSK9) blocks the low-density lipoprotein receptors (LDL-R) and, as a consequence, low-density lipoprotein cholesterol (LDL-C) levels increase. Therefore, PCSK9 has emerged as a potential… read more here.
Keywords: small molecule; pcsk9 inhibitors; molecule pcsk9; pcsk9 ... See more keywords
Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.173114
Abstract: The clinical benefit of lipid-lowering therapies is to reduce circulating levels of atherogenic particles and to ameliorate the risk of atherosclerotic cardiovascular disease (ASCVD). The completion of two major clinical trials on PCSK9 inhibitors (PCSK9i),… read more here.
Keywords: pcsk9 inhibitors; clinical trials; lipid lowering; therapy ... See more keywords
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.11.072
Abstract: Mendelian randomization studies and randomized trials have conclusively demonstrated that lower low-density lipoprotein (LDL) cholesterol results in fewer cardiovascular events. This review describes key stages in the evolution of LDL cholesterol-lowering treatment. Data from over… read more here.
Keywords: pcsk9 inhibitors; ldl cholesterol; lipid modifying; modifying agents ... See more keywords